Cmxtwenty
Milwaukee
About Cmxtwenty
Cmxtwenty is a Milwaukee based pharmaceutical company focused on the development of a unique lipid compound to be used as a non-narcotic treatment for pain. Established in November 2004, Cmxtwenty received its initial funding through an SBIR grant from the National Institute on Drug Abuse (NIDA). Since 2007, Cmxtwenty has been funded privately by a network of individual investors. Their lead product, CMX-020, is an analog of arachidonic acid, a common endogenous lipid and one of the most abundant lipids for cell signaling in the brain. Cmxtwenty maintains international patent filings on CMX-020 through 2029. Phase 1 clinical studies are currently ongoing.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.7M
- Last round: Series Unknown (May 2016)
- Website: cytometix.com
- Phone: 414-745-8000
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cmxtwenty-184059 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.